{"id":"motrin-percocet-dilaudid-for-breakthrough","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Gastrointestinal upset (from NSAID)"}]},"_chembl":{"chemblId":"CHEMBL521875","moleculeType":"Small molecule","molecularWeight":"460.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Motrin (ibuprofen) is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes to reduce inflammation and pain. Percocet (oxycodone/acetaminophen) combines an opioid mu-receptor agonist with acetaminophen for moderate-to-severe pain. Dilaudid (hydromorphone) is a potent mu-opioid receptor agonist used for severe breakthrough pain. Together, this multimodal approach targets pain through both inflammatory and opioid pathways.","oneSentence":"This is a combination regimen using ibuprofen (NSAID), oxycodone/acetaminophen (opioid analgesic), and hydromorphone (potent opioid) for managing breakthrough pain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:55.357Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breakthrough pain management in opioid-tolerant patients"},{"name":"Moderate-to-severe acute pain"}]},"trialDetails":[{"nctId":"NCT03987022","phase":"PHASE4","title":"ICE-T Pain Regimen for Total Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2019-08-01","conditions":"Opioid Substitution Treatment","enrollment":66},{"nctId":"NCT03052816","phase":"PHASE4","title":"Ice T Postoperative Multimodal Pain Regimen in FPMRS Surgery","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2017-04-01","conditions":"Pain, Postoperative, Pelvic Organ Prolapse","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Motrin/Percocet/Dilaudid for breakthrough","genericName":"Motrin/Percocet/Dilaudid for breakthrough","companyName":"University Hospitals Cleveland Medical Center","companyId":"university-hospitals-cleveland-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination regimen using ibuprofen (NSAID), oxycodone/acetaminophen (opioid analgesic), and hydromorphone (potent opioid) for managing breakthrough pain. Used for Breakthrough pain management in opioid-tolerant patients, Moderate-to-severe acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}